Browse Categories

Publications by authors named "Mohammed Abdul-Matin"

  • Page 1 of 1
Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.
Ali S Omrani Mustafa M Saad Kamran Baig Abdelkarim Bahloul Mohammed Abdul-Matin

Lancet Infect Dis

November 2014

Background: Middle East respiratory syndrome coronavirus (MERS-CoV) infection is associated with high mortality and has no approved antiviral therapy. We aimed to compare ribavirin and interferon alfa-2a treatment for patients with severe MERS-CoV infection with a supportive therapy only.

Methods: In this retrospective cohort study, we included adults (aged ≥16 years) with laboratory-confirmed MERS-CoV infection and pneumonia needing ventilation support, diagnosed between Oct 23, 2012, and May 1, 2014, at the Prince Sultan Military Medical City (Riyadh, Saudi Arabia).

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Mohammed Abdul-Matin"

  • - Mohammed Abdul-Matin's research primarily focuses on the treatment of severe infections caused by coronaviruses, particularly Middle East respiratory syndrome (MERS-CoV), highlighting the urgent need for effective antiviral therapies.
  • - In his 2014 study published in "Lancet Infect Dis", he conducted a retrospective cohort analysis comparing the efficacy of ribavirin combined with interferon alfa-2a against supportive therapy alone in patients with severe MERS-CoV infection.
  • - The findings of this research emphasize the high mortality associated with MERS-CoV and indicate the necessity for further investigations into antiviral treatments for better management of severe cases.

Privacy Policy Site Map

© LitMetric 2024. All rights reserved.